1.22
0.00%
+0.00
Molecular Templates Inc stock is currently priced at $1.22, with a 24-hour trading volume of 73,534.
It has seen a +0.00% increased in the last 24 hours and a -26.51% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.17 pivot point. If it approaches the $1.32 resistance level, significant changes may occur.
Previous Close:
$1.22
Open:
$1.18
24h Volume:
73,534
Market Cap:
$8.03M
Revenue:
$52.63M
Net Income/Loss:
$-8.12M
P/E Ratio:
-0.098
EPS:
-12.45
Net Cash Flow:
$-42.02M
1W Performance:
-2.40%
1M Performance:
-26.51%
6M Performance:
-75.00%
1Y Performance:
+159.57%
Molecular Templates Inc Stock (MTEM) Company Profile
Name
Molecular Templates Inc
Sector
Industry
Phone
512 869 1555
Address
9301 Amberglen Boulevard, Suite 100, Austin, TX
Molecular Templates Inc Stock (MTEM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-21-21 | Initiated | BofA Securities | Buy |
Feb-01-21 | Initiated | UBS | Neutral |
Sep-08-20 | Initiated | Jefferies | Buy |
Mar-25-20 | Initiated | Stifel | Buy |
Feb-27-20 | Initiated | Barclays | Overweight |
Apr-29-19 | Initiated | UBS | Buy |
Dec-11-18 | Initiated | Oppenheimer | Outperform |
Oct-08-18 | Initiated | Laidlaw | Buy |
View All
Molecular Templates Inc Stock (MTEM) Latest News
Biopharma Layoff Tracker 2024: Takeda, Evotec, Lyra and More Cut Staff - BioSpace
BioSpace
Financial Health Check: Examining Molecular Templates Inc (MTEM)'s Key Ratios – DWinneX - The Dwinnex
The Dwinnex
Biopharma Layoff Tracker 2024: Evotec, Lyra, Takeda and More Cut Staff - BioSpace
BioSpace
Biopharma Layoff Tracker 2024: Evotec, Lyra, Takeda and More Cut Staff - BioSpace
BioSpace
Biopharma Layoff Tracker 2024: Evotec, Lyra, Takeda and More Cut Staff - BioSpace
BioSpace
Biopharma Layoff Tracker 2024: Evotec, Lyra, Takeda and More Cut Staff - BioSpace
BioSpace
Molecular Templates Inc Stock (MTEM) Financials Data
Molecular Templates Inc (MTEM) Revenue 2024
MTEM reported a revenue (TTM) of $52.62 million for the quarter ending December 31, 2023, a +166.40% rise year-over-year.
Molecular Templates Inc (MTEM) Net Income 2024
MTEM net income (TTM) was -$8.12 million for the quarter ending December 31, 2023, a +91.24% increase year-over-year.
Molecular Templates Inc (MTEM) Cash Flow 2024
MTEM recorded a free cash flow (TTM) of -$42.02 million for the quarter ending December 31, 2023, a +54.44% increase year-over-year.
Molecular Templates Inc (MTEM) Earnings per Share 2024
MTEM earnings per share (TTM) was -$1.63 for the quarter ending December 31, 2023, a +93.36% growth year-over-year.
About Molecular Templates Inc
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Cap:
|
Volume (24h):